© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
IASLC North America
Phase III CANOPY Studies to Investigate Canakinumab in NSCLC
October 15, 2019
The agent has a high affinity and specificity for interleukin-1 beta.
Pembrolizumab Shows Benefit for NSCLC Patients with Brain Metastases
October 15, 2019
The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.
Neutrophil-to-Lymphocyte Ratio Helps Predict Survival in Stage III NSCLC
October 12, 2019
NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.